切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2022, Vol. 10 ›› Issue (01) : 32 -38. doi: 10.3877/cma.j.issn.2095-5782.2022.01.006

肿瘤介入

基于肿瘤负荷评分评估TACE联合MWA治疗转移性肝癌的预后
朱炳橙1, 田伟1, 周春1, 施海彬1, 刘圣1,()   
  1. 1. 210029 江苏南京,南京医科大学第一附属医院介入放射科
  • 收稿日期:2021-06-21 出版日期:2022-02-25
  • 通信作者: 刘圣

Prognosis of TACE combined with MWA in the treatment of liver metastases based on tumor burden score

Bingcheng Zhu1, Wei Tian1, Chun Zhou1, Haibin Shi1, Sheng Liu1,()   

  1. 1. Department of Interventional Radiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Nanjing 210029, China
  • Received:2021-06-21 Published:2022-02-25
  • Corresponding author: Sheng Liu
引用本文:

朱炳橙, 田伟, 周春, 施海彬, 刘圣. 基于肿瘤负荷评分评估TACE联合MWA治疗转移性肝癌的预后[J]. 中华介入放射学电子杂志, 2022, 10(01): 32-38.

Bingcheng Zhu, Wei Tian, Chun Zhou, Haibin Shi, Sheng Liu. Prognosis of TACE combined with MWA in the treatment of liver metastases based on tumor burden score[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(01): 32-38.

目的

评估肝动脉化疗栓塞术(TACE)联合微波消融术(MWA)治疗胃肠道转移性肝癌的有效性和安全性。探究肿瘤负荷评分(TBS)预测转移性肝癌患者术后生存预后的效能。

方法

回顾性分析2015年1月至2020年4月于我院接受TACE联合MWA治疗的54例转移性肝癌患者临床资料,所有患者原发病灶均为胃肠道恶性肿瘤,分析局部肿瘤控制、生存结果、不良反应。采用TBS评估患者的肿瘤负荷,将患者分组并行组间比较:低负荷组(TBS≤3,n = 24)和高负荷组(3 < TBS < 6,n = 30)。使用时间依赖的ROC曲线及曲线下面积(AUC)分析评估TBS预测无进展生存期(PFS)和总生存期(OS)的能力。

结果

54例转移性肝癌患者术后客观缓解率(ORR)为88.9%,疾病控制率(DCR)为96.3%。中位随访期为21.5个月,中位PFS和OS分别为8.2个月、23.8个月。术后半年、1年、2年、3年OS率分别为96.2%、79.2%、41.8%、24.3%。低负荷组和高负荷组中位PFS分别为9.8个月和6.6个月;两组中位OS分别为27.2个月和17.3个月。ROC曲线分析显示,TBS预测患者术后PFS和OS的AUC分别为0.720和0.606,高于肿瘤最大直径的AUC(0.695和0.575)和肿瘤数目的AUC(0.586和0.483)。不同肿瘤负荷组围手术期均无明显严重并发症。

结论

TACE联合MWA是治疗胃肠道癌肝转移患者的一种安全、有效的治疗方式,能够显著改善局部肿瘤控制和延长患者总生存期。TBS可较好地预测胃肠道癌肝转移患者TACE联合MWA术后的生存预后情况。

Objective

To evaluate the efficiency and safety of transarterial chemoembolization (TACE) combined with microwave ablation (MWA, TACE-MWA) in patients with liver metastases from gastrointestinal cancers. To explore the ability of tumor burden score (TBS) in predicting the prognosis of patients with liver metastases after TACE-MWA.

Methods

This retrospective study involved 54 patients with liver metastases from gastrointestinal cancers who underwent TACE plus MWA between January 2015 and April 2020 in our hospital. Local tumor control, survival outcomes and complications were evaluated. TBS was used to evaluate the tumor burden of the patient. Patients were divided into low tumor burden group (TBS≤3, n = 24) and high tumor burden group (3 < TBS < 6, n = 30) and differences between the two groups were made. Time-dependent ROC analysis was conducted to evaluate the ability of TBS in predicting progression-free survival (PFS) and overall survival (OS).

Results

The objective response rate (ORR) was 88.9% and the disease control rate (DCR) was 96.3% of the 54 patients. The median follow-up period was 21.5 months. Patients had a median PFS of 8.2 months and a median OS of 23.8 months. The 0.5-, 1- , 2-, and 3-year OS rates were 96.2%, 79.2%, 41.8%, and 24.3% respectively. The median PFS and OS were 9.8, 27.2 months in the low tumor burden group versus 6.6, 17.3 months in the high tumor burden group respectively (P < 0.05). Time-dependent ROC analysis showed that the AUC of TBS for predicting PFS and OS were 0.720 and 0.606, higher than that of maximum tumor diameter (0.695 and 0.575) and tumor number (0.586 and 0.483). No major complication related to treatment was observed in the two groups.

Conclusions

TACE-MWA is a safe and effective treatment option for patients with liver metastases from gastrointestinal cancers with improved disease control and prolonged overall survival. TBS may be a good tool for predicting the prognosis of patients with liver metastases after TACE-MWA.

表1 患者基线资料
图1 一例66岁男患者的转移性肝癌TACE联合MWA治疗前后对比1A:TACE术前腹部CT示单发结节,直径4.2 cm,TBS 4.3,病灶(白色箭头所示)呈不均匀强化;1B:TACE术中DSA示病灶(白色箭头所示)呈结节状、染色不明显;1C:TACE术后3周腹部CT示病灶(白色箭头所示)碘油沉积欠佳;1D~1E:MWA术中CT证实消融针(针尖如黑色箭头所示)进入病灶后,以50 W消融7 min,调整消融针角度及深度,再次以50 W消融5 min;1F:TACE联合MWA术后2个月腹部增强CT示病灶(白色箭头所示)内见坏死区及碘油沉积区,肿瘤反应评定为CR。
表2 患者疗效分析
图2 不同肿瘤负荷组患者TACE联合MWA术后Kaplan-Meier曲线2A:无进展生存期(PFS)Kaplan-Meier曲线;2B:总生存期(OS)Kaplan-Meier曲线。
图3 肿瘤负荷评分(TBS)、肿瘤最大直径和肿瘤数目预测患者TACE联合MWA术后ROC曲线3A:无进展生存期(PFS)ROC曲线;3B:总生存期(OS)ROC曲线。
[1]
Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma[J]. Clin Oncol, 2005, 23(9): 2038-2048.
[2]
Akgul O, Cetinkaya E, Ersoz S, et al. Role of surgery in colorectal cancer liver metastases[J]. World J Gastroenterol, 2014, 20(20): 6113-6122.
[3]
Massmann A, Rodt T, Marquardt S, et al. Transarterial chemoembolization (TACE) for colorectal liver metastases—current status and critical review[J]. Langenbecks Arch Surg, 2015, 400(6): 641-659.
[4]
刘海宽, 陈文川, 刘一铭, 等. 肝动脉栓塞术治疗42例低-中级别乏血供型神经内分泌肿瘤肝转移的近期疗效及安全性分析[J]. 中华介入放射学电子杂志, 2020, 8(2): 130-134.
[5]
张超, 李非, 李昂, 等. 肝动脉化疗栓塞治疗原发病灶切除的胰腺神经内分泌肿瘤肝转移疗效分析[J]. 介入放射学杂志2020, 29(8): 772-776.
[6]
王舒婷, 陈海波, 施昌盛, 等. 经皮射频消融联合125I放射性粒子植入术治疗肝恶性肿瘤的疗效分析[J]. 介入放射学杂志, 2020, 29(6): 587-590.
[7]
Galanakis N, Kehagias E, Matthaiou N, et al. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review[J]. Hepat Oncol, 2018, 5(2): HEP07.
[8]
Xu Z, Xie H, Zhou L, et al. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma[J]. Anal Cell Pathol (Amst), 2019, 2019: 8619096.
[9]
Wu ZB, Si ZM, Qian S, et al. Percutaneous microwave ablation combined with synchronous transcatheter arterial chemoembolization for the treatment of colorectal liver metastases: results from a follow-up cohort[J]. OncoTargets Ther, 2016, 9: 3783-3789.
[10]
许伟, 顾玉明, 王兴田, 等. 超声造影引导下微波消融联合TACE治疗肝转移瘤[J]. 介入放射学杂志, 2012, 21(10): 821-824.
[11]
Vogl TJ, Lahrsow M, Albrecht MH, et al. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation[J]. Eur J Radiol, 2018, 102: 138-145.
[12]
Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients[J]. Am Coll Surg, 2010, 210(5): 755-764.
[13]
Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea[J]. Stat Med, 2006, 25(1): 127-141.
[14]
Sasaki K, Morioka D, Conci S, et al. The tumor burden score:a new "Metro-ticket" prognostic tool for colorectal liver metastases based on tumor size and number of tumors[J]. Ann Surg, 2018, 267(1): 132-141.
[15]
王言焱, 刘佳明, 王立军, 等. 肿瘤负荷评分在肝细胞癌患者预后预测中的价值[J]. 中国癌症防治杂志, 2019, 11(5): 393-397.
[16]
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60.
[17]
Gruber-Rouh T, Marko C, Thalhammer A, et al. Current strategies in interventional oncology of colorectal liver metastases[J]. Br J Radiol, 2016, 89(1064): 20151060.
[18]
Vogl TJ, Gruber-Rouh T, Eichler K, et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results[J]. Eur J Radiol, 2013, 82(2): 258-263.
[19]
Zhang H, Guo J, Gao S, et al. Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis[J]. Chin J Cancer Res, 2017, 29(1): 36-44.
[1] 谢迎东, 孙帼, 徐超丽, 杨斌, 孙晖, 戴云. 超声造影定量评价不同生存期移植肾血流灌注的临床价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 749-754.
[2] 刘娅, 刘政, 冯爽, 董睿, 陈晓琴, 益磋. 超声联合微泡对兔VX2肿瘤化疗效果的影响[J]. 中华医学超声杂志(电子版), 2021, 18(07): 705-709.
[3] 董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[4] 赵敬柱, 郑向前, 高明, 池嘉栋, 运新伟, 李大鹏, 阮先辉. 散发性甲状腺髓样癌原发灶的切除范围及预后分析[J]. 中华普通外科学文献(电子版), 2021, 15(06): 429-431.
[5] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[6] 贾洪涛, 倪庆强, 于泽涛, 卢俊, 常宏. 肝癌自发性破裂出血的治疗及预后研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 408-412.
[7] 佟凯军, 刘大振, 汤坤龙, 杨长海. 后腹腔镜下肾部分切除与根治性肾切除治疗T1期肾癌的疗效分析[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 142-146.
[8] 杨发才, 游川, 雷正清, 李伟男, 段安琪, 邱应和, 李敬东, 程张军. 肿瘤负荷评分联合淋巴结分期对肝内胆管细胞癌患者术后生存预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 389-394.
[9] 刘恩瑞, 关旭, 魏然, 姜争, 刘正, 陈瑛罡, 王锡山. 新辅助治疗反应对局部进展期直肠癌患者预后的影响[J]. 中华结直肠疾病电子杂志, 2022, 11(01): 44-53.
[10] 萨仁高娃, 张英霞, 邓伟, 闫诺, 樊宁. 超声引导下鼠肝消融术后组织病理特征的变化规律及影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 394-398.
[11] 胡旭华, 于淼, 柳鹏辉, 张建锋, 李保坤, 王晓然, 郭甘霖, 于滨, 张振亚, 王贵英. 同时性多原发结直肠癌临床病理特征及生存分析[J]. 中华临床医师杂志(电子版), 2021, 15(11): 833-841.
[12] 吴雅琴, 莫伟, 向华, 李琴, 李玉莲, 周碧芳. 肝癌患者介入术后股动脉穿刺处出血的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 352-356.
[13] 许晨, 俞靖凡, 方昌文, 张志轩, 徐国雄, 金一琦. 经皮金属多支架置入治疗BismuthⅡ型及以上肝门部胆管癌的临床应用分析[J]. 中华介入放射学电子杂志, 2023, 11(02): 123-127.
[14] 任健吾, 刘圣, 施海彬, 杨魏, 田伟, 周卫忠. 经左侧远桡动脉入路在肝动脉化疗栓塞术中的应用[J]. 中华介入放射学电子杂志, 2022, 10(03): 241-244.
[15] 刘仕锦, 张怡然, 丁晖, 赵晓旭, 潘运龙. 代谢综合征与端粒状态对结直肠癌患者预后的影响[J]. 中华肥胖与代谢病电子杂志, 2022, 08(04): 231-235.
阅读次数
全文


摘要